Larry Gitelman
Psychiatric/Mental Health · Weirton, WVNPI 1568438539
Payments from drug & device makers
What this record shows
Almost everything reported here is food and beverage — 98.5% of the total across 117 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. 24 manufacturers reported payments, led by ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.) at 24.8% of the total. Reporting peaked in 2022 at $952 and has fallen 57.2% since, to $408 in 2025. Among psychiatric/mental health clinicians in WV with any reported payments, this total sits in the top 10% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 117 payments — averaging $29.12 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.)$846
- Johnson & Johnson$631
- AbbVie$484
- Otsuka America Pharmaceutical, Inc.$410
- Takeda Pharmaceuticals U.S.A., Inc.$284
- Alkermes, Inc.$233
- plus $519 from 18 others
What the payments were for
- Food & beverage$3,35699%
- Education$501%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.) | 14 | $846 |
| Johnson & Johnson | 11 | $631 |
| AbbVie | 20 | $484 |
| Otsuka America Pharmaceutical, Inc. | 24 | $410 |
| Takeda Pharmaceuticals U.S.A., Inc. | 19 | $284 |
| Alkermes, Inc. | 3 | $233 |
| Jazz Pharmaceuticals Inc. | 1 | $91 |
| Boehringer Ingelheim | 5 | $78 |
| Esperion Therapeutics, Inc. | 2 | $35 |
| Lilly USA, LLC | 2 | $33 |
| Currax Pharmaceuticals LLC | 2 | $29 |
| Verona Pharma, Inc. | 1 | $28 |
| Mylan Specialty L.p. | 1 | $26 |
| Merck | 2 | $26 |
| Viatris Specialty LLC | 1 | $24 |
| Teva Pharmaceuticals USA, Inc. | 1 | $21 |
| Scynexis, Inc. | 1 | $18 |
| Novo Nordisk | 1 | $18 |
| Avanir Pharmaceuticals, Inc. | 1 | $17 |
| Pfizer | 1 | $16 |
| Sanofi Pasteur Inc. | 1 | $16 |
| Amarin Pharma, Inc. | 1 | $14 |
| Philips North America LLC | 1 | $14 |
| Dexcom, Inc. | 1 | $14 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$3,407 in reported general payments places this provider in the 90th percentile of 142 psychiatric/mental health providers in West Virginia.
See all psychiatric/mental health providers in West Virginia →
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Invega SustennaPaliperidone Palmitate | 47 | $147,898 |
| Abilify MaintenaAripiprazole | 20 | $56,312 |
| VraylarCariprazine Hcl | 22 | $30,057 |
| RexultiBrexpiprazole | 13 | $17,320 |
| TrintellixVortioxetine Hydrobromide | 14 | $6,741 |
| Ziprasidone Hcl | 30 | $2,738 |
| Atomoxetine Hcl | 29 | $2,093 |
| Duloxetine Hcl | 194 | $2,020 |
| Quetiapine Fumarate | 201 | $1,855 |
| Aripiprazole | 112 | $1,736 |
| Bupropion XlBupropion Hcl | 171 | $1,657 |
| Quetiapine Fumarate ErQuetiapine Fumarate | 41 | $1,396 |
| Venlafaxine Hcl ErVenlafaxine Hcl | 84 | $1,275 |
| Prazosin Hcl | 108 | $1,215 |
| Hydroxyzine Pamoate | 107 | $1,212 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Johnson & JohnsonInvega Sustenna | $631 | $147,89847 claims |
| Otsuka America Pharmaceutical, Inc.Abilify Maintena, Rexulti | $410 | $73,63233 claims |
| AbbVieVraylar | $484 | $30,05722 claims |
| Takeda Pharmaceuticals U.S.A., Inc.Trintellix | $284 | $6,74114 claims |
| Lilly USA, LLCOlanzapine | $33 | $42737 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 142 psychiatric/mental health providers in West Virginia.
Other psychiatric/mental health in Weirton
- Jessica DickeyWeirton$2K
- Jeremy SchreiberWheeling$1.7M
- Kimberly RittenhouseParkersburg$7K
- Michael SkaggsRipley$7K
- Larry RobertsonHuntington$6K
- Gwendolyn HuffmanSummersville$6K
- Summer DevolParkersburg$5K
- Osric Malone-PrioleauSaint Marys$5K
- Mercedes WeikleFort Gay$5K
- Shannon PembertonBarboursville$4K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.